Status:

NOT_YET_RECRUITING

A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder

Lead Sponsor:

Second Xiangya Hospital of Central South University

Conditions:

Depressive Disorder, Major

Cognitive Impairment

Eligibility:

All Genders

18-45 years

Phase:

NA

Brief Summary

Persistent cognitive impairment in major depressive disorder (MDD) affects both treatment outcomes and psychosocial functioning, emphasizing the critical need for effective treatment. However, there i...

Detailed Description

This is a mechanistic clinical trial investigating the neural basis of cognitive flexibility (CF) impairment in major depressive disorder (MDD) and the therapeutic effects of targeted neuromodulation....

Eligibility Criteria

Inclusion

  • Meets DSM-5 criteria for Major Depressive Episode confirmed by two attending psychiatrists using SCID-5
  • Currently in depressive episode (MADRS ≥22)
  • Stable dose of SSRIs/SNRIs for ≥4 weeks prior to randomization
  • Age 18-45 years
  • Han Chinese ethnicity, right-handed
  • Minimum junior high school education; no color blindness; capable of providing informed consent
  • Willing to sign informed consent and complete all assessments

Exclusion

  • Other DSM-5 psychiatric disorders (except MDD)
  • Received non-pharmacotherapy in past 6 months:
  • ECT
  • rTMS
  • Systematic psychotherapy (\>10 sessions)
  • Prior CCRT treatment
  • Medications affecting cognition within specified washout periods:
  • Antipsychotics (1 month)
  • Cholinesterase inhibitors (donepezil:14d; galantamine:2d)
  • Memantine (20d)
  • Nootropics (e.g., piracetam:2d)
  • Significant medical comorbidities:
  • Thyroid disorders, SLE, diabetes
  • Hepatic/renal/pulmonary impairment
  • Active infections
  • Major trauma
  • History of traumatic brain injury with coma
  • Substance/alcohol abuse or dependence
  • Active suicidal ideation/attempt (MADRS item 10 ≥4)
  • Current corticosteroid therapy
  • Pregnancy, lactation, or planned pregnancy
  • Personal/family history of epilepsy
  • Metallic implants (e.g., pacemaker, dental prostheses)
  • Investigator-determined contraindications

Key Trial Info

Start Date :

September 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2028

Estimated Enrollment :

182 Patients enrolled

Trial Details

Trial ID

NCT07161492

Start Date

September 1 2025

End Date

October 1 2028

Last Update

September 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xiangya Second Hospital of Central South University

Changsha, Hunan, China, 410011